JP2022512900A5 - - Google Patents
Info
- Publication number
- JP2022512900A5 JP2022512900A5 JP2021523897A JP2021523897A JP2022512900A5 JP 2022512900 A5 JP2022512900 A5 JP 2022512900A5 JP 2021523897 A JP2021523897 A JP 2021523897A JP 2021523897 A JP2021523897 A JP 2021523897A JP 2022512900 A5 JP2022512900 A5 JP 2022512900A5
- Authority
- JP
- Japan
- Prior art keywords
- represented
- formula
- bifunctional compound
- group
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862754934P | 2018-11-02 | 2018-11-02 | |
| US62/754,934 | 2018-11-02 | ||
| PCT/US2019/059401 WO2020092907A1 (en) | 2018-11-02 | 2019-11-01 | Acetylation writer inhibitor development and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022512900A JP2022512900A (ja) | 2022-02-07 |
| JP2022512900A5 true JP2022512900A5 (cg-RX-API-DMAC7.html) | 2022-11-08 |
| JP7712867B2 JP7712867B2 (ja) | 2025-07-24 |
Family
ID=70463920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523897A Active JP7712867B2 (ja) | 2018-11-02 | 2019-11-01 | アセチル化ライター阻害剤の開発およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12428412B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3873898B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7712867B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN112969696B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019371400B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3118597A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3038078T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020092907A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| CN111217802B (zh) * | 2018-11-27 | 2021-10-08 | 海创药业股份有限公司 | 一类组蛋白乙酰化酶p300抑制剂及其用途 |
| AU2019389174A1 (en) | 2018-11-30 | 2021-07-01 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| CN113646002A (zh) * | 2019-02-27 | 2021-11-12 | 上海睿跃生物科技有限公司 | 环amp反应元件结合蛋白(cbp)和/或300kda腺病毒e1a结合蛋白(p300)降解化合物和使用方法 |
| EP3986470A4 (en) * | 2019-06-18 | 2023-10-04 | Dana-Farber Cancer Institute, Inc. | TARGETED SMALL MOLECULE BROMO/ACETYL PROTEINS AND THEIR USES |
| PH12022500002A1 (en) | 2019-06-28 | 2023-04-03 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| US12558427B2 (en) | 2019-07-17 | 2026-02-24 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| WO2021119159A1 (en) | 2019-12-10 | 2021-06-17 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| CA3161878A1 (en) | 2019-12-17 | 2021-06-24 | Matthew M. Weiss | Irak degraders and uses thereof |
| AU2021316053A1 (en) | 2020-07-30 | 2023-03-02 | Kymera Therapeutics, Inc. | Methods of treating mutant lymphomas |
| CN116507333B (zh) * | 2020-08-27 | 2025-05-09 | 上海睿跃生物科技有限公司 | 环amp反应元件结合蛋白(cbp)和/或300kda腺病毒e1a结合蛋白(p300)降解化合物和使用方法 |
| US20240122941A1 (en) * | 2020-12-25 | 2024-04-18 | National Cancer Center | Therapy based on synthetic lethality in swi/snf complex-dysfunction cancer |
| AR124547A1 (es) | 2020-12-30 | 2023-04-05 | Kymera Therapeutics Inc | Degradadores de irak y sus usos |
| EP4304572A4 (en) * | 2021-03-09 | 2025-02-12 | Dana-Farber Cancer Institute, Inc. | EP300 DEGRADER AND USES THEREOF IN NEUROBLASTOMA |
| JP2024540080A (ja) | 2021-10-29 | 2024-10-31 | カイメラ セラピューティクス, インコーポレイテッド | Irak4分解剤およびその合成 |
| CN116375717B (zh) * | 2021-12-30 | 2025-10-28 | 成都先导药物开发股份有限公司 | 螺环化合物及其双功能化合物和用途 |
| EP4472967A4 (en) | 2022-01-31 | 2026-04-15 | Kymera Therapeutics Inc | Iraqi Degradation Agents and Their Uses |
| GB202209404D0 (en) * | 2022-06-27 | 2022-08-10 | Univ Of Sussex | Compounds |
| JP2025137900A (ja) * | 2022-08-10 | 2025-09-25 | 住友ファーマ株式会社 | 第4級炭素で置換された3級アミド誘導体 |
| JP7856847B2 (ja) * | 2022-09-07 | 2026-05-11 | 成都先導薬物開発股▲フン▼有限公司 | スピロ化合物及びその用途 |
| CN119255996B (zh) * | 2022-09-08 | 2026-04-24 | 成都先导药物开发股份有限公司 | 螺环化合物及其用途 |
| WO2024064358A1 (en) * | 2022-09-23 | 2024-03-28 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| AU2023358062A1 (en) | 2022-10-07 | 2025-03-20 | Pfizer Inc. | Hsd17b13 inhibitors and/or degraders |
| WO2024127297A1 (en) | 2022-12-16 | 2024-06-20 | Pfizer Inc. | 3-fluoro-4-hydroxybenzmide-containing inhibitors and/or degraders and uses thereof |
| CN116178339B (zh) * | 2023-02-20 | 2024-08-06 | 杭州医学院 | 以含氧烷烃为连接链的hdac降解剂及其制备方法和应用 |
| GB202302941D0 (en) | 2023-02-28 | 2023-04-12 | Tocris Cookson Ltd | Proteolysis-targeting chimeras |
| AU2024395784A1 (en) | 2023-12-07 | 2026-06-11 | Pfizer Inc. | Biphenyl and phenylpyridine compounds as inhibitors of kat2a and/or kat2b |
| WO2026088071A1 (en) | 2024-10-23 | 2026-04-30 | Pfizer Inc. | Substituted fused heteroaryl lactam compounds |
| WO2026154417A1 (en) | 2025-01-17 | 2026-07-23 | Pfizer Inc. | Fused heterocyclic amide/sulfonamide compounds as agonists of the calcitonin/amylin receptors for the treatment of obesity |
| WO2026159633A1 (en) | 2025-01-24 | 2026-07-30 | Pfizer Inc. | 4-(2-(dimethylamino)-2-oxoethyl)-3-methyl-5-oxo-2,3,4,5-tetrahydrobenzofuro[2,3-f][1,4]oxazepine-3-carboxamide compounds and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| US9345705B2 (en) | 2011-09-15 | 2016-05-24 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer |
| US20160235716A1 (en) | 2014-09-18 | 2016-08-18 | Abbvie Inc. | Spirocyclic hat inhibitors and methods for their use |
| GB201519196D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
| BR112018008918A8 (pt) | 2015-11-02 | 2019-02-26 | Univ Yale | compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos |
| CN109562113A (zh) * | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
| WO2017197046A1 (en) * | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| MX2019004950A (es) * | 2016-10-28 | 2019-09-26 | Icahn School Med Mount Sinai | Composiciones y metodos para tratar el cancer mediado por el potenciador del homologo zeste 2. |
| IL315310A (en) * | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| EP3986470A4 (en) * | 2019-06-18 | 2023-10-04 | Dana-Farber Cancer Institute, Inc. | TARGETED SMALL MOLECULE BROMO/ACETYL PROTEINS AND THEIR USES |
-
2019
- 2019-11-01 AU AU2019371400A patent/AU2019371400B2/en active Active
- 2019-11-01 WO PCT/US2019/059401 patent/WO2020092907A1/en not_active Ceased
- 2019-11-01 CA CA3118597A patent/CA3118597A1/en active Pending
- 2019-11-01 JP JP2021523897A patent/JP7712867B2/ja active Active
- 2019-11-01 EP EP19878099.1A patent/EP3873898B1/en active Active
- 2019-11-01 US US17/289,662 patent/US12428412B2/en active Active
- 2019-11-01 CN CN201980072584.4A patent/CN112969696B/zh active Active
- 2019-11-01 ES ES19878099T patent/ES3038078T3/es active Active
-
2025
- 2025-07-08 US US19/262,282 patent/US20250333402A1/en active Pending